LUNDBECK SYMPOSIUM

2nd NEUROPSYCHIATRIC SYMPOSIUM ON ALZHEIMER’S DISEASE AND DEPRESSION

22 July 2018 • 09.00 – 16.00
Le Meridien Hotel, Jakarta
Speakers & Topics
The Role of Language and Communication in
Alzheimer’s Disease
Prof. Dr. dr. Moh. Hasan Machfoed, SpS (K)
Consultant Neurologist & Senior Lecturer,
Dr. Soetomo Hospital Surabaya
Head of Indonesian Neurologist Association
Can We Prevent Behavioral and Psychological
Symptoms of Dementia (BPSD)
Dr. dr. Paulus Anam Ong, SpS (K)
Consultant Neurologist & Senior Lecturer,
Hasan Sadikin Hospital Bandung
Optimal Dosing of Pharmacology Treatment in Dementia
Associate Prof. Nagaendran Kandiah, MBBS., MRCP., FAMS
Senior Consultant Neurologist, National Neuroscience
Institute
Programme Director, NNI Dementia Programme
Clinician-Scientist, National Medical Research
Lundbeck Exsport A/S
Indonesia Trade Representative Office
Menara Jamsostek 12A
Jl. Jend. Gatot Subroto No. 38 Jakarta 12710
Phone : +62 21 52901132 Fax :
LUNDBECK SYMPOSIUM
nd
2 NEUROPSYCHIATRIC SYMPOSIUM ON ALZHEIMER’S DISEASE AND DEPRESSION
Functional Recovery in MDD – Going Beyond MADRS
Dr. dr. Nurmiati Amir, SpKJ (K)
Consultant Psychiatrist & Senior Lecturer,
Dr. Cipto Mangunkusumo Hospital Jakarta
Real World Study of Vortioxetine In Depressed
Asian Patient (ReVida)
FEEL• THINK• DO BETTER
Dr. Keira Joann Herr, PhD
Medical Manager
Lundbeck South East Asia, Singapore
What You Should Know Before Prescribe Vortioxetine
Prof. Pierre Blier, M.D., Ph.D.
Brain and Mind Research Institute, Royal Ottawa
Institute of Mental Health Research
President-Elect of The International College of
Neuropsychopharmacology (CINP)
22 July 2018 • 09.00 – 16.00
Take care of more than mood
Le Meridien Hotel, Jakarta
+62 21 52901132
 6

152
million
7 150

120
82
million
90

6 60

30

8 0
2030 2050

PROGRESS Lundbeck is one of the only pharmaceutical companies in the world entirely focused on Depression, Schizophrenia, Parkinson’s disease and Alzheimer’s disease, we have developed and marketed leading medicines for these diseases during the past century.
Over the years, millions of people have been treated with our products and our development and distribution of pioneering treatments continues to make a difference to patients worldwide.
Reference: 1. World Health Organization. Depression fact sheet. 2017. (http://www.who.int/mediacentre/factsheets/fs369/en/). 2. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;

IN MIND
12(1): 321. Erratum in: Int J Methods Psychiatr Res 2003; 12(3): 165. 3. Kessler R, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys. Epidemiol Psychiatr Soc 2009; 18(1): 23-33. 4. Conradi H, Ormel J, De Jonge P. Presence of individual (residual) symptoms during
depressive episodes and periods of remission: A 3-year prospective study. Psychol Med 2011; 41(6): 1165-1174. 5. IDEA: Impact of Depression at Work in Europe Audit Final report. Ipsos Healthcare. October 2012. 6. World Health Organization. Dementia fact sheet. 2017 (http://www.who.int/mediacentre/factsheets/fs362/en/). 7. World Health Organization.
Dementia - A public health priority. 2017(http://www.who.int/mental_health/neurology/dementia/infographic_dementia/en/) 8. Bird TD. Alzheimer Disease Overview. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 19932016. 2016. (http://www.ncbi.nlm.nih.gov/-
books/NBK1161/).